Cynosure's TriActive(TM) Laser System Receives Health Canada Approval for Temporary Reduction in Appearance of Cellulite
January 18 2006 - 7:30AM
PR Newswire (US)
Company Gains Over-the-Counter Clearance for Canada WESTFORD,
Mass., Jan. 18 /PRNewswire-FirstCall/ -- Cynosure, Inc.
(NASDAQ:CYNO), a leading developer and manufacturer of lasers and
pulsed light sources, today announced it has received Class II
medical device license approval from Health Canada to market and
sell its laser-based TriActive(TM) LaserDermology(SM) System for
the temporary reduction in the appearance of cellulite, over the
counter in Canada. The TriActive is Cynosure's flagship cellulite
product that contains six low-energy diode lasers, mechanical
massage and suction and localized cooling. "We are delighted to
further the availability of this proven treatment for the reduction
of cellulite's appearance," said Michael R. Davin, Chairman and CEO
of Cynosure. "TriActive is the only laser-based system that can be
sold over the counter both in the United States and Canada for the
temporary reduction of cellulite's appearance, providing us with a
significant competitive advantage. The approval by Canada's
regulatory body allows us to better serve the Canadian market with
an expanded product offering and helps us enhance our share of the
rapidly growing emerging cellulite market." Cellulite is a deposit
of fat that causes a dimple or other uneven appearance of the skin
on women, typically around the hips, thighs and buttocks. According
to published reports, an estimated 80 percent of women have some
degree of cellulite. This condition is far more common in women
than men due to the way fat, muscle and connective tissues are
distributed in women's skin. Cynosure believes that more than 50
million women in the US and Canada between the ages of 20 and 50
suffer from this condition, with many seeking treatment options.
"With the addition of TriActive to our practice, we have seen an
increase in patients looking for an effective treatment of
cellulite," commented Roger Lam, MD, medical director of Infinity
Laser Center in Sherway Gardens, Toronto. "Patients are excited to
discover a scientifically proven technique that temporarily reduces
unsightly cellulite. This treatment has been instrumental in
reducing the appearance of cellulite on the waist, thighs and
buttocks. Patients love how easy and relaxing the treatments are."
In addition to temporarily reducing the appearance of cellulite,
TriActive treatments have also been shown to temporarily relieve
minor pain and muscle spasms. About Cynosure, Inc. Cynosure, Inc.
develops and markets aesthetic treatment systems that are used by
physicians and other practitioners to perform non-invasive
procedures to remove hair, treat vascular lesions, rejuvenate skin
through the treatment of shallow vascular and pigmented lesions and
temporarily reduce the appearance of cellulite. Cynosure's products
include a broad range of laser and other light-based energy
sources, including Alexandrite, pulse-dye, Nd:YAG and diode lasers,
as well as intense pulsed light. Cynosure was founded in 1991. For
corporate or product information, contact Cynosure at 800-886-2966,
or visit http://www.cynosurelaser.com/. Any statements in this
press release about future expectations, plans and prospects for
Cynosure, Inc., including statements about the markets in which
Cynosure's products are sold, and other statements containing the
words "believes," "anticipates," "plans," "expects," "will," and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including Cynosure's history of operating losses, its
reliance on sole source suppliers, competition in the aesthetic
laser industry, economic, market, technological and other factors
discussed in Cynosure's Registration Statement on Form S-1, as
amended, filed with the SEC. In addition, the forward-looking
statements included in this press release represent Cynosure's
views as of the date of this press release. Cynosure anticipates
that subsequent events and developments will cause its views to
change. However, while Cynosure may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Cynosure's views as of any date subsequent to the date
of this press release. First Call Analyst: FCMN Contact:
DATASOURCE: Cynosure, Inc. CONTACT: Timothy W. Baker of Cynosure,
Inc., +1-800-886-2966, Web site: http://www.cynosurelaser.com/
Copyright